Tufts Center for the Study of Drug Development (CSDD) and clinical trial platform company Medable recently announced an analysis estimating that Medable’s Clinical Monitoring Agent could deliver an 82x return on investment for phase 3 trials and 64x for phase 2. Based on expected net present value (eNPV), that equated to roughly $21 million in…
TransCelerate CEO Janice Chang wants trials to become part of routine care
Clinical trials are drowning in data. In a TransCelerate/Tufts analysis published in late 2025, phase 3 protocols averaged more than 5.9 million data points, up 67% since 2020. The researchers found that nearly one-third of procedures and associated data were non-core or non-essential. In other words, a good portion of this data does not directly…

